Zacks: Brokerages Anticipate Kindred Biosciences Inc (KIN) Will Post Earnings of -$0.37 Per Share

Share on StockTwits

Equities analysts expect that Kindred Biosciences Inc (NASDAQ:KIN) will post earnings of ($0.37) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Kindred Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.36). Kindred Biosciences reported earnings of ($0.39) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 5.1%. The firm is expected to report its next earnings results on Thursday, August 8th.

On average, analysts expect that Kindred Biosciences will report full year earnings of ($1.45) per share for the current fiscal year, with EPS estimates ranging from ($1.60) to ($1.24). For the next financial year, analysts expect that the company will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.21) to ($0.83). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $1.95 million.

A number of analysts have weighed in on KIN shares. Lake Street Capital decreased their target price on shares of Kindred Biosciences from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 7th. Cantor Fitzgerald set a $25.00 price target on Kindred Biosciences and gave the stock a “buy” rating in a research note on Friday, April 26th. Zacks Investment Research lowered Kindred Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Kindred Biosciences in a research note on Thursday, March 7th. Finally, BidaskClub lowered Kindred Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $17.11.

NASDAQ KIN traded down $0.26 during trading hours on Friday, reaching $8.41. The company’s stock had a trading volume of 3,618 shares, compared to its average volume of 178,237. The firm has a market cap of $351.05 million, a PE ratio of -5.23 and a beta of 0.37. Kindred Biosciences has a 52 week low of $8.04 and a 52 week high of $15.75. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.10 and a quick ratio of 8.70.

A number of hedge funds and other institutional investors have recently modified their holdings of KIN. Bank of New York Mellon Corp raised its position in Kindred Biosciences by 24.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 90,847 shares of the biopharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 17,798 shares in the last quarter. BlackRock Inc. raised its position in Kindred Biosciences by 38.1% during the 3rd quarter. BlackRock Inc. now owns 1,829,393 shares of the biopharmaceutical company’s stock valued at $25,520,000 after purchasing an additional 504,246 shares in the last quarter. Man Group plc bought a new stake in Kindred Biosciences during the 3rd quarter valued at $942,000. MetLife Investment Advisors LLC raised its position in Kindred Biosciences by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 21,274 shares of the biopharmaceutical company’s stock valued at $297,000 after purchasing an additional 7,563 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in Kindred Biosciences by 28.6% during the 3rd quarter. Teachers Advisors LLC now owns 57,607 shares of the biopharmaceutical company’s stock valued at $804,000 after purchasing an additional 12,810 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Recommended Story: Forex

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.